- Home
- ENTX vs LPTX Comparison
ENTX vs LPTX Comparison
Compare ENTX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- LPTX
- Stock Information
- Founded
- ENTX 2010
- LPTX 2011
- Country
- ENTX Israel
- LPTX United States
- Employees
- ENTX N/A
- LPTX N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTX Health Care
- LPTX Health Care
- Exchange
- ENTX Nasdaq
- LPTX Nasdaq
- Market Cap
- ENTX 104.0M
- LPTX 119.6M
- IPO Year
- ENTX 2018
- LPTX N/A
- Fundamental
- Price
- ENTX $1.98
- LPTX $0.38
- Analyst Decision
- ENTX Strong Buy
- LPTX Buy
- Analyst Count
- ENTX 1
- LPTX 2
- Target Price
- ENTX $10.00
- LPTX $8.00
- AVG Volume (30 Days)
- ENTX 43.1K
- LPTX 321.1K
- Earning Date
- ENTX 08-08-2025
- LPTX 08-11-2025
- Dividend Yield
- ENTX N/A
- LPTX N/A
- EPS Growth
- ENTX N/A
- LPTX N/A
- EPS
- ENTX N/A
- LPTX N/A
- Revenue
- ENTX $223,000.00
- LPTX N/A
- Revenue This Year
- ENTX N/A
- LPTX N/A
- Revenue Next Year
- ENTX N/A
- LPTX N/A
- P/E Ratio
- ENTX N/A
- LPTX N/A
- Revenue Growth
- ENTX N/A
- LPTX N/A
- 52 Week Low
- ENTX $1.41
- LPTX $0.22
- 52 Week High
- ENTX $2.79
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ENTX 48.00
- LPTX 46.09
- Support Level
- ENTX $1.87
- LPTX $0.38
- Resistance Level
- ENTX $2.18
- LPTX $0.44
- Average True Range (ATR)
- ENTX 0.18
- LPTX 0.04
- MACD
- ENTX -0.00
- LPTX -0.00
- Stochastic Oscillator
- ENTX 31.82
- LPTX 22.52
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .